CureVac and WACKER Sign Manufacturing Contract for CureVac’s COVID-19 Vaccine Candidate, CVnCoV
- WACKER SUPPORTS CUREVAC IN THE PRODUCTION OF ITS MRNA-BASED VACCINE CANDIDATE AGAINST COVID-19
- MANUFACTURING AT WACKER´S BIOTECH SITE IN AMSTERDAM IS SCHEDULED TO START IN THE FIRST HALF OF 2021
CureVac N.V., a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), and Wacker Chemie AG announced today that they had signed a contract for the manufacturing of CureVac’s COVID-19 vaccine candidate CVnCoV. Under the terms of the initial agreement, WACKER will ramp up GMP (Good Manufacturing Practice) production of the mRNA drug substance for CVnCoV at its biotech site in Amsterdam in the first half of 2021. Preparations for the start of production, technology transfers and test runs are already underway. It is planned to produce more than 100 million doses of the CureVac vaccine per year at WACKER’s Amsterdam site. There is
also further potential for expansion at the site in order to meet rising
demand in the future.